Сравнительный экономический анализ клопидогрела и тикагрелора при остром коронарном синдроме [PDF]
Качественная клиническая практика, 2018 Актуальность. Клинико-экономический анализ, основанный на моделировании процессов по сценарию PLATO применительно к российской действительности, учитывающий НПР (частоту, тяжесть, диагностику, медикаментозное лечение, длительность пребывания в стационаре
doaj +2 more sources
Analysis of the structure of consumption of antiplatelet drugs in the Russian pharmaceutical market: 2014-2016 [PDF]
Качественная клиническая практика, 2018 This article analyzes the volume of the Russian pharmaceutical market of antiplatelet drugs in the period 2014-2016. 80% of patients take clopidogrel generics, giving preference to Zilt®.
S. K. Zyryanov, E. V. Dumchenko
doaj +2 more sources
Review the results of pharmacoeconomic trials of antiplatelet drugs in the treatment of patients with acute coronary syndrome [PDF]
Качественная клиническая практика, 2018 The purpose of this literature review is to systematize and synthesis of the available data for the period 20132016 years of pharmacoeconomics evaluation on the application of modern antiplatelet agents in patients with acute coronary syndrome (ACS ...
S. K. Zyryanov, E. V. Dumchenko
doaj +2 more sources
Антиагрегантная терапия при остром коронарном синдроме [PDF]
, 2022 Cardiovascular diseases are currently the most common causes of death worldwide, and most deaths from cardiovascular diseases are associated with coronary artery disease (CAD).
D. S. Markhuliya +7 more
core +2 more sources
Current views on antiplatelet therapy in acute coronary syndrome patients: the place of clopidogrel [PDF]
, 2022 Clopidogrel is the most studied P2Y12 receptor blocker and still has no alternative in a number of categories of ACS patients in whom ticagrelor or prasugrel have not been studied or their use is associated with an unacceptably high risk of bleeding. The
O. O. Shakhmatova
core +4 more sources
The Problem of Drug Interactions Between Rosuvastatin and Ticagrelor in the Aspect of the Risk of Rhabdomyolysis: Discussion of the Problem and Description of the Clinical Case [PDF]
, 2022 Background. Combination therapy with two antiplatelet agents (ticagrelor or clopidogrel plus acetylsalicylic acid) and a high dose statin is recommended in accordance with clinical guidelines for patients undergoing acute coronary syndrome and coronary ...
M. V. Leonova +2 more
core +3 more sources
Efficiency and safety of various dual antiplatelet therapy strategies in patients undergoing percutaneous coronary intervention due to myocardial infarction [PDF]
, 2021 Aim. To compare the efficacy and safety of prasugrel, ticagrelor, or clopidogrel as part of dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention (PCI) due to myocardial infarction (MI).Material and methods.
A. V. Solovieva +2 more
core +2 more sources
Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice? [PDF]
, 2020 Dual antiplatelet therapy is the most important step in acute coronary syndrome (ACS) treatment. The new generation of inhibitors of P2Y12 platelet receptors (prasugrel and ticagrelor) provide more pronounced platelet inhibition than clopidogrel.
A. S. Tereshchenko, T. M. Uskach
core +2 more sources
Selection of P2Y12 antagonist in patients with myocardial infarction who received thrombolytic therapy. Results of annual follow-up of TREAT study patients [PDF]
, 2019 Dual antiplatelet therapy serves to improve the clinical results of thrombolytic therapy after STEMI, until recently consisted of acetylsalicylic acid and clopidogrel.
O. V. Averkov, V. I. Vechorko
core +2 more sources
Фармакоэкономический анализ применения антитромботической терапии у пациентов с острым коронарным синдромом, а также у пациентов с фибрилляцией предсердий, подвергшихся чрескожному коронарному вмешательству [PDF]
, 2023 Objective: to assess the clinical and economic feasibility of ticagrelor in combination with acetylsalicylic acid (ASA) in comparison with clopidogrel in combination with ASA in patients with acute coronary syndrome (ACS), including both those who ...
D. G. Shchurov +7 more
core +2 more sources